HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Josep Tabernero

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital and Director of the Vall d’Hebron Institute of Oncology (VHIO). He is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumour-directed targeted therapies and immune therapies.

Based on the idea that each tumor has an independent genetic identity, his research aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team´s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has (co) authored approximately 400 peer-reviewed papers.

He is currently President (2018 – 2019) of the European Society for Medical Oncology´s (ESMO), and is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO).

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551